Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07783542
PHASE2

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Sponsor: Oruka Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blinded, placebo-controlled clinical study of ORKA-002 in adult participants with moderate-to-severe HS.

Official title: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Key Details

Gender

All

Age Range

18 Years - 79 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2026-08-20

Completion Date

2029-09

Last Updated

2026-08-31

Healthy Volunteers

No

Interventions

DRUG

ORKA-002

ORKA-002 administered by subcutaneous (SC) injection

OTHER

Placebo

Placebo administered by subcutaneous (SC) injection

Locations (2)

Oruka Therapeutics Investigative Site

Chapel Hill, North Carolina, United States

Oruka Therapeutics Investigative Site

Dallas, Texas, United States